Respiratory

Respiratory drugs and is a growing sector of the pharmaceuticals industry, and we have all the information resources that you need to be a leading player in this lucrative market. The publications listed under Research and Markets’ Respiratory category cover all drugs and therapeutics for conditions and diseases relating to the lungs and/or breathing, such as Acute Respiratory Distress Syndrome (ARDS), allergy, asthma, bronchitis, COPD (chronic obstructive pulmonary disease), cystic fibrosis, emphysema, lung disease, pneumonia, sinus infections, sleep apnea and others.

Our reports, books, and subscriptions will provide you with the latest industry news, forecasts, market trends and company profiles of market leaders and niche players including: Accentia Biopharmaceuticals, Aerogen, Aerovance, airPharma, AstraZeneca, Aventis Pharma, Bespak, Boehringer Ingelheim Pharmaceuticals, Cadila Pharmaceuticals, Dr. Reddys Laboratories, EvoGenix, GlaxoSmithKlineInyx, The Merck Generics Group, Novartis AG, Pfizer, Ranbaxy Laboratories, Respironics, Sandoz International, Schering-Plough, etc.

Publications on smoking cessation are listed under the OTC sub-category in the Pharmaceuticals section. Show Less ... more

• Respiratory Insufficiency Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 77
  Respiratory Insufficiency Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Respiratory Insufficiency Global Clinical Trials Review, H2, 2011" provides data on the...

• Sleep Apnea Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 108
  Sleep Apnea Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Sleep Apnea Global Clinical Trials Review, H2, 2011" provides data on the Sleep Apnea clinical trial...

• Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 68
  Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2,...

• Adult Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 67
  Adult Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Adult Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2011"...

• COPD Market Forecast

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Nov 2011 , Pages: 6
  New product launches for COPD across the seven major markets will override generic erosion and boost market value from $8.2bn in 2011 to $9.6bn by 2020, representing a positive 2011–20 CAGR of 1.8%....

• Bronchiolitis Obliterans - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Nov 2011 , Pages: 38
  Bronchiolitis Obliterans - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Bronchiolitis Obliterans - Pipeline Review, H2 2011', provides an overview of the Bronchiolitis Obliterans therapeutic...

• Emphysema - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Nov 2011 , Pages: 45
  Emphysema - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Emphysema - Pipeline Review, H2 2011', provides an overview of the Emphysema therapeutic pipeline. This report provides information...

• Pulmonary Fibrosis - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Nov 2011 , Pages: 112
  Pulmonary Fibrosis - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Pulmonary Fibrosis - Pipeline Review, H2 2011', provides an overview of the Pulmonary Fibrosis therapeutic pipeline....

• Lung Injury - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Nov 2011 , Pages: 74
  Lung Injury - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Lung Injury - Pipeline Review, H2 2011', provides an overview of the Lung Injury therapeutic pipeline. This report provides...

• Market and Product Forecasts: COPD - Growth expected despite untapped market potential

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Nov 2011 , Pages: 77
  New product launches for COPD across the seven major markets will override generic erosion and boost market value from $8.2bn in 2011 to $9.6bn by 2020, representing a positive 2011–20 CAGR of 1.8%....

• Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GBI Research, Nov 2011 , Pages: 76
  GBI Research’s report, “Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD”, provides an in-depth analysis of patient recruitment scenario for...

• Respiratory Depression Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 53
  Respiratory Depression Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Respiratory Depression Global Clinical Trials Review, H2, 2011" provides data on the Respiratory...

• Obstructive Sleep Apnea Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 118
  Obstructive Sleep Apnea Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Obstructive Sleep Apnea Global Clinical Trials Review, H2, 2011" provides data on the Obstructive...

• Acute Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 98
  Acute Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Acute Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2011"...

• Pulmonary Embolism Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 112
  Pulmonary Embolism Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Pulmonary Embolism Global Clinical Trials Review, H2, 2011" provides data on the Pulmonary Embolism...

• Respiratory Tract Infections Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2011 , Pages: 127
  Respiratory Tract Infections Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Respiratory Tract Infections Global Clinical Trials Review, H2, 2011" provides data...

• Product Profiles: COPD in China - Novel therapies to diversify treatment options

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Nov 2011 , Pages: 89
  Spiriva has a strong reputation with Chinese physicians due to its robust efficacy, making it the gold standard monotherapy in COPD treatment. Spiriva’s inclusion in the 2009 National Reimbursement...

• Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GlobalData, Nov 2011 , Pages: 73
  Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Summary GlobalData, the industry analysis specialist, has released its new report, “Pneumonia Therapeutics - Pipeline Assessment...

• Industry Outlook: Trends in Respiratory Disease Strategies

  EURO€ 1,768.00USD$ 2,300.00GBP£ 1,487.00AUD$ 2,250.00JPY¥ 227,086.00SEK 15 101,00CHF 2'168.00CAD$ 2,344.00 Decision Resources, Inc, Nov 2011
  The market for respiratory drugs has already proven lucrative for pharmaceutical developers and marketers, supporting multiple blockbuster brands and steady annual sales increases Pharmaceutical manufacturers...

• Acute Lung Injury Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Oct 2011 , Pages: 87
  Acute Lung Injury Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Acute Lung Injury Global Clinical Trials Review, H2, 2011" provides data on the Acute Lung Injury...

• Pulmonary Arterial Hypertension Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Oct 2011 , Pages: 109
  Pulmonary Arterial Hypertension Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Pulmonary Arterial Hypertension Global Clinical Trials Review, H2, 2011" provides...

• Emphysema Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Oct 2011 , Pages: 102
  Emphysema Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Emphysema Global Clinical Trials Review, H2, 2011" provides data on the Emphysema clinical trial scenario....

• Diphtheria Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Oct 2011 , Pages: 82
  Diphtheria Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Diphtheria Global Clinical Trials Review, H2, 2011" provides data on the Diphtheria clinical trial scenario....

• Bronchitis Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Oct 2011 , Pages: 100
  Bronchitis Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Bronchitis Global Clinical Trials Review, H2, 2011" provides data on the Bronchitis clinical trial scenario....

• Product Profiles: Asthma/COPD - Novel Combinations Edge Closer to Market

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Oct 2011 , Pages: 157
  Despite a number of well-established therapies, the asthma/COPD pipeline remains highly active. A number of products have progressed in the pipeline and significant new data have been presented at this...

• Acute Respiratory Distress Syndrome - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Oct 2011 , Pages: 60
  Acute Respiratory Distress Syndrome - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Acute Respiratory Distress Syndrome - Pipeline Review, H2 2011', provides an overview of the Acute...

• Bronchiectasis - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Oct 2011 , Pages: 62
  Bronchiectasis - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Bronchiectasis - Pipeline Review, H2 2011', provides an overview of the Bronchiectasis therapeutic pipeline. This report...

• Cough - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Oct 2011 , Pages: 57
  Cough - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Cough - Pipeline Review, H2 2011', provides an overview of the Cough therapeutic pipeline. This report provides information on the...

• Respiratory Depression - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Oct 2011 , Pages: 30
  Respiratory Depression - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Respiratory Depression - Pipeline Review, H2 2011', provides an overview of the Respiratory Depression therapeutic...

• Asthma: KOL Insights on Treatment Practices and Unmet Needs

  EURO€ 2,148.00USD$ 2,795.00GBP£ 1,808.00AUD$ 2,734.00JPY¥ 275,959.00SEK 18 352,00CHF 2'634.00CAD$ 2,848.00 Sociable Pharma, Oct 2011 , Pages: 92
  In-depth primary research was conducted in the US and across Europe with six key opinion leaders to understand how changes will impact therapy use in the future During the European Respiratory Society's...

• Chronic Obstructive Pulmonary Disease (COPD): KOL Insights on Treatment Practices and Unmet Needs

  EURO€ 2,148.00USD$ 2,795.00GBP£ 1,808.00AUD$ 2,734.00JPY¥ 275,959.00SEK 18 352,00CHF 2'634.00CAD$ 2,848.00 Sociable Pharma, Oct 2011 , Pages: 99
  In-depth primary research was conducted in the US and across Europe with seven key opinion leaders to understand how changes will impact therapy use in the future During the European Respiratory Society's...

• The Pricing and Reimbursement Environment for Respiratory Disease Therapies

  EURO€ 3,536.00USD$ 4,600.00GBP£ 2,975.00AUD$ 4,499.00JPY¥ 454,172.00SEK 30 203,00CHF 4'336.00CAD$ 4,687.00 Decision Resources, Inc, Oct 2011
  Common respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) make up a large and varied pharmaceutical market sector These diseases also impose a significant burden on...

• Asthma - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Sep 2011 , Pages: 189
  Asthma - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Asthma - Pipeline Review, H2 2011', provides an overview of the Asthma therapeutic pipeline. This report provides information on...

• Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Sep 2011 , Pages: 155
  Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2011', provides an overview...

• Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Sep 2011 , Pages: 93
  Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2011', provides an overview of the Idiopathic Pulmonary...

• Bronchitis - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Sep 2011 , Pages: 47
  Bronchitis - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Bronchitis - Pipeline Review, H2 2011', provides an overview of the Bronchitis therapeutic pipeline. This report provides information...

• Pneumonia - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Sep 2011 , Pages: 169
  Pneumonia - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Pneumonia - Pipeline Review, H2 2011', provides an overview of the Pneumonia therapeutic pipeline. This report provides information...

• The Respiratory Disease Pipeline: A Competitive Review

  EURO€ 3,536.00USD$ 4,600.00GBP£ 2,975.00AUD$ 4,499.00JPY¥ 454,172.00SEK 30 203,00CHF 4'336.00CAD$ 4,687.00 Decision Resources, Inc, Sep 2011
  Despite the availability of a plethora of symptomatic treatments, many common chronic respiratory diseases - such as asthma and chronic obstructive pulmonary disorder (COPD) - lack curative therapies...

• Biomarker and Diagnostic Opportunities in Respiratory Diseases

  EURO€ 1,768.00USD$ 2,300.00GBP£ 1,487.00AUD$ 2,250.00JPY¥ 227,086.00SEK 15 101,00CHF 2'168.00CAD$ 2,344.00 Decision Resources, Inc, Sep 2011
  Although the molecular diagnostics field may not be as robust in respiratory diseases as it is in other therapeutic areas that have a high prevalence and a lively pharmaceutical market, the prospects...

• Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GBI Research, Sep 2011 , Pages: 171
  “Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries” provides insights into the global respiratory...

• Pulmonary Embolism - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Aug 2011 , Pages: 34
  Pulmonary Embolism - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Pulmonary Embolism - Pipeline Review, H2 2011', provides an overview of the Pulmonary Embolism therapeutic pipeline....

• Bronchopulmonary Dysplasia - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Aug 2011 , Pages: 56
  Bronchopulmonary Dysplasia - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Bronchopulmonary Dysplasia - Pipeline Review, H2 2011', provides an overview of the Bronchopulmonary Dysplasia...

• Bronchiolitis - Pipeline Review, H2 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Aug 2011 , Pages: 52
  Bronchiolitis - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Bronchiolitis - Pipeline Review, H2 2011', provides an overview of the Bronchiolitis therapeutic pipeline. This report provides...

• Diphtheria - Pipeline Review, H2 20111

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Aug 2011 , Pages: 62
  Diphtheria - Pipeline Review, H2 20111 Summary Global Markets Direct’s, 'Diphtheria - Pipeline Review, H2 2011', provides an overview of the Diphtheria therapeutic pipeline. This report provides information...

• Respiratory Distress Syndrome - Pipeline Review, Q3 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Jul 2011 , Pages: 92
  Respiratory Distress Syndrome - Pipeline Review, Q3 2011 Summary Global Markets Direct’s, 'Respiratory Distress Syndrome - Pipeline Review, Q3 2011', provides an overview of the Respiratory Distress...

• Acute Lung Injury - Pipeline Review, Q3 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Jul 2011 , Pages: 72
  Acute Lung Injury - Pipeline Review, Q3 2011 Summary Global Markets Direct’s, 'Acute Lung Injury - Pipeline Review, Q3 2011', provides an overview of the Acute Lung Injury therapeutic pipeline. This...

• Respiratory Syncytial Virus (Rsv) Infection - Pipeline Review, Q3 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Jul 2011 , Pages: 82
  Respiratory Syncytial Virus (Rsv) Infection - Pipeline Review, Q3 2011 Summary Global Markets Direct’s, 'Respiratory Syncytial Virus (Rsv) Infection - Pipeline Review, Q3 2011', provides an overview...

• Altitude Sickness (Acute Mountain Sickness) - Pipeline Review, Q3 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Jul 2011 , Pages: 21
  Altitude Sickness (Acute Mountain Sickness) - Pipeline Review, Q3 2011 Summary Global Markets Direct’s, 'Altitude Sickness (Acute Mountain Sickness) - Pipeline Review, Q3 2011', provides an overview...

• Sleep Apnea - Pipeline Review, Q3 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Jul 2011 , Pages: 65
  Sleep Apnea - Pipeline Review, Q3 2011 Summary Global Markets Direct’s, 'Sleep Apnea - Pipeline Review, Q3 2011', provides an overview of the Sleep Apnea therapeutic pipeline. This report provides...

• Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Jul 2011 , Pages: 62
  Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Summary GlobalData, the industry analysis specialist, has released its new report, “Acute...